As a result of recent trials, two HDAC inhibitors, romidepsin and belinostat, have been approved by the FDA for use in relapsed/refractory PTCL [3, 60, 61]. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.